Developer docs
API playgroundTry for free, no card

Search company profiles

Yoshindo

Full company profile

uuid000i3b9

Namestring
Yoshindo
Legal namestring
Yoshindo Holdings Inc.
Websiteurl
yoshindo.co.jp
Company typeenum
Private
Founded yearint
1929
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToyama-shi, Japan
HQ citystring
Toyama-shi
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, biosimilar manufacturing, essential medicines, biopharmaceutical products, infusion dialysis solutions
Industry1 code
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1FlexFactory™
Description

Biosimilar manufacturing platform implemented in collaboration with Cytiva for producing antibody drug active pharmaceutical ingredients

yoshindoholdings.co.jp
Core offering1 text field

Yoshindo is a Japanese pharmaceutical manufacturer that produces and supplies generic drugs, essential medicines, biopharmaceuticals (including biosimilars), health foods, and infusion/dialysis solutions. The company distributes its products through pharmaceutical wholesalers to hospitals, clinics, and pharmacies across Japan. Yoshindo is also building biosimilar manufacturing capacity using Cytiva's FlexFactory™ platform, targeting antibody drug API production by 2028.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Yoshindo Holdings is a pharmaceutical company operating multiple business segments including generic drugs, essential drugs, biopharmaceuticals (biosimilars), health foods, and infusion/dialysis solutions. The company is expanding into biosimilar manufacturing with Cytiva's FlexFactory™ technology, targeting production start by 2028. The portfolio is organized into distinct product categories under unified corporate governance.

Product and service6 records
1Generic Drugs (ジェネリック医薬品)
CategoryGeneric Pharmaceuticals
Description

Yoshindo's generic pharmaceutical products offering cost-effective alternatives to brand-name medications for hospitals, clinics, pharmacies, and patients in Japan.

2Essential Drugs (エッセンシャルドラッグ)
CategoryEssential Medicines
Description

Essential medicines addressing fundamental healthcare needs, supplied to medical institutions across Japan.

3Biopharmaceuticals (バイオ医薬品)
CategoryBiopharmaceuticals
Description

Biologic drugs including biosimilars, with a focus on antibody drug active pharmaceutical ingredients for the biopharmaceutical market.

4Health Foods (健康食品)
CategoryHealth Foods
Description

Nutritional and health supplement products supporting consumer wellness, distributed through Yoshindo's healthcare channels.

5Infusion/Dialysis Solutions (輸液・透析液)
CategoryMedical Solutions
Description

Intravenous solutions and dialysis fluids for medical treatment, supplied to hospitals and clinics in Japan.

6Biosimilar Manufacturing System (Cytiva FlexFactory™)
CategoryBiosimilar Manufacturing
Description

A comprehensive biosimilar manufacturing system established in Japan with Cytiva's FlexFactory™ technology, targeting production start by 2028 for antibody drug biosimilar active pharmaceutical ingredients.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-22
Description

Yoshindo has established a biosimilar manufacturing system in Japan with support from Cytiva's FlexFactory™ technology. The partnership aims to start production by 2028, focusing on biosimilar active pharmaceutical ingredients for antibody drugs. The collaboration positions Yoshindo to capitalize on significant market growth forecasts in the biosimilar sector.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Sawai Group Holdings
TypeDirect peer
Description

Sawai is the largest Japanese generic pharmaceutical manufacturer with broad generic and biosimilar activities — directly comparable to Yoshindo's generic and emerging biosimilar focus in the Japan market.

2Towa Pharmaceutical
TypeDirect peer
Description

Towa is a top-tier Japanese generic drug manufacturer with diversified dosage forms and growing biosimilar activity — directly comparable to Yoshindo's generic + biosimilar positioning.

3Nichi-Iko Pharmaceutical
TypeDirect peer
Description

Nichi-Iko is a leading Japanese generic pharmaceutical company with an extensive off-patent portfolio — closely comparable to Yoshindo's generic FDF manufacturing base.

4Fuji Pharma
TypeDirect peer
Description

Fuji Pharma is a Japanese specialty generic and biosimilar manufacturer with a portfolio spanning injectables and biosimilars — directly comparable to Yoshindo's generic and biosimilar activities.

5Mochida Pharmaceutical
TypeDirect peer
Description

Mochida is a mid-sized Japanese pharmaceutical manufacturer with a focus on specialty and biosimilar products — comparable to Yoshindo's diversified generic + biopharma profile.

TypeBroad incumbent
Description

Kyowa Kirin is a major Japanese specialty biopharma company with biologic and biosimilar activities — a broader incumbent operating in the same therapeutic categories and Japan market as Yoshindo.

7Chugai Pharmaceutical
TypeBroad incumbent
Description

Chugai is one of Japan's largest biopharmaceutical companies with a strong biologics franchise — a broader incumbent representative of the competitive landscape for Yoshindo's biosimilar ambitions.

TypeBroad incumbent
Description

Daiichi Sankyo is a top-tier Japanese pharma major with both innovative and biosimilar operations — a broader incumbent that competes at scale against Yoshindo's biosimilar entry.

TypeBroad incumbent
Description

Astellas is a leading Japanese biopharmaceutical company with established biologics and biosimilar capabilities — a broader incumbent in Yoshindo's therapeutic and operational space.

TypeBroad incumbent
Description

Takeda is Japan's largest pharmaceutical manufacturer with global biosimilar and biologic operations — a broader incumbent representative of Japan's ultimate competitive ceiling for Yoshindo.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yoshindo

Generic Pharmaceuticalsyoshindo.co.jp

Yoshindo firmographics

Firmographics
Name
Yoshindo
Legal name
Yoshindo Holdings Inc.
Website
https://yoshindo.co.jp
Company type
Private
Founded year
1929
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Yoshindo industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Generic pharmaceuticals
  • Biosimilar manufacturing
  • Essential medicines
  • Biopharmaceutical products
  • Infusion dialysis solutions

Where Yoshindo is headquartered

Location

Headquarters

HQ city
Toyama-shi
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Yoshindo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Yoshindo product offering

Product offering

Core offering

Yoshindo is a Japanese pharmaceutical manufacturer that produces and supplies generic drugs, essential medicines, biopharmaceuticals (including biosimilars), health foods, and infusion/dialysis solutions. The company distributes its products through pharmaceutical wholesalers to hospitals, clinics, and pharmacies across Japan. Yoshindo is also building biosimilar manufacturing capacity using Cytiva's FlexFactory™ platform, targeting antibody drug API production by 2028.

Product overview

Yoshindo Holdings is a pharmaceutical company operating multiple business segments including generic drugs, essential drugs, biopharmaceuticals (biosimilars), health foods, and infusion/dialysis solutions. The company is expanding into biosimilar manufacturing with Cytiva's FlexFactory™ technology, targeting production start by 2028. The portfolio is organized into distinct product categories under unified corporate governance.

Differentiator

Problem solved

Functional benefit

Brands

  • FlexFactory™: Biosimilar manufacturing platform implemented in collaboration with Cytiva for producing antibody drug active pharmaceutical ingredients

Products and services

  • Generic Drugs (ジェネリック医薬品) Yoshindo's generic pharmaceutical products offering cost-effective alternatives to brand-name medications for hospitals, clinics, pharmacies, and patients in Japan.
  • Essential Drugs (エッセンシャルドラッグ) Essential medicines addressing fundamental healthcare needs, supplied to medical institutions across Japan.
  • Biopharmaceuticals (バイオ医薬品) Biologic drugs including biosimilars, with a focus on antibody drug active pharmaceutical ingredients for the biopharmaceutical market.
  • Health Foods (健康食品) Nutritional and health supplement products supporting consumer wellness, distributed through Yoshindo's healthcare channels.
  • Infusion/Dialysis Solutions (輸液・透析液) Intravenous solutions and dialysis fluids for medical treatment, supplied to hospitals and clinics in Japan.
  • Biosimilar Manufacturing System (Cytiva FlexFactory™) A comprehensive biosimilar manufacturing system established in Japan with Cytiva's FlexFactory™ technology, targeting production start by 2028 for antibody drug biosimilar active pharmaceutical ingredients.

Companies that use Yoshindo

Customer profile

Segments2 records

Ideal customer profiles2 records

Yoshindo technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Yoshindo partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CytivacoreStrategic or Co-development Partner · 22 March 2026Yoshindo has established a biosimilar manufacturing system in Japan with support from Cytiva's FlexFactory™ technology. The partnership aims to start production by 2028, focusing on biosimilar active pharmaceutical ingredients for antibody drugs. The collaboration positions Yoshindo to capitalize on significant market growth forecasts in the biosimilar sector.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Yoshindo competitors and assessment

Company assessment

Direct peers

  • Sawai Group Holdings: Sawai is the largest Japanese generic pharmaceutical manufacturer with broad generic and biosimilar activities — directly comparable to Yoshindo's generic and emerging biosimilar focus in the Japan market.
  • Towa Pharmaceutical: Towa is a top-tier Japanese generic drug manufacturer with diversified dosage forms and growing biosimilar activity — directly comparable to Yoshindo's generic + biosimilar positioning.
  • Nichi-Iko Pharmaceutical: Nichi-Iko is a leading Japanese generic pharmaceutical company with an extensive off-patent portfolio — closely comparable to Yoshindo's generic FDF manufacturing base.
  • Fuji Pharma: Fuji Pharma is a Japanese specialty generic and biosimilar manufacturer with a portfolio spanning injectables and biosimilars — directly comparable to Yoshindo's generic and biosimilar activities.
  • Mochida Pharmaceutical: Mochida is a mid-sized Japanese pharmaceutical manufacturer with a focus on specialty and biosimilar products — comparable to Yoshindo's diversified generic + biopharma profile.

Broad incumbents

  • Kyowa Kirin: Kyowa Kirin is a major Japanese specialty biopharma company with biologic and biosimilar activities — a broader incumbent operating in the same therapeutic categories and Japan market as Yoshindo.
  • Chugai Pharmaceutical: Chugai is one of Japan's largest biopharmaceutical companies with a strong biologics franchise — a broader incumbent representative of the competitive landscape for Yoshindo's biosimilar ambitions.
  • Daiichi Sankyo: Daiichi Sankyo is a top-tier Japanese pharma major with both innovative and biosimilar operations — a broader incumbent that competes at scale against Yoshindo's biosimilar entry.
  • Astellas Pharma: Astellas is a leading Japanese biopharmaceutical company with established biologics and biosimilar capabilities — a broader incumbent in Yoshindo's therapeutic and operational space.
  • Takeda Pharmaceutical: Takeda is Japan's largest pharmaceutical manufacturer with global biosimilar and biologic operations — a broader incumbent representative of Japan's ultimate competitive ceiling for Yoshindo.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Yoshindo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yoshindo leadership team

Management profile

Number of profiles

Yoshindo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yoshindo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yoshindo

What does Yoshindo do?

Yoshindo is a Japanese pharmaceutical manufacturer that produces and supplies generic drugs, essential medicines, biopharmaceuticals (including biosimilars), health foods, and infusion/dialysis solutions. The company distributes its products through pharmaceutical wholesalers to hospitals, clinics, and pharmacies across Japan. Yoshindo is also building biosimilar manufacturing capacity using Cytiva's FlexFactory™ platform, targeting antibody drug API production by 2028.

Is Yoshindo a public or private company?

Yoshindo is a private company. It is classified as unknown and is currently operating.

When was Yoshindo founded?

Yoshindo was founded in 1929. It employs 1 to 10 people.

Where is Yoshindo based?

Yoshindo is headquartered in Toyama-shi, Japan, in the Asia region.

Who are Yoshindo's main competitors?

Direct peers on record are Sawai Group Holdings, Towa Pharmaceutical, Nichi-Iko Pharmaceutical, Fuji Pharma and Mochida Pharmaceutical. Broad incumbents are Kyowa Kirin, Chugai Pharmaceutical, Daiichi Sankyo, Astellas Pharma and Takeda Pharmaceutical.

Does Yoshindo have an API?

No public API is recorded for Yoshindo.

What industry is Yoshindo in?

Yoshindo's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals